Search

Your search keyword '"Medica D"' showing total 84 results
Start Over Author "Medica D"
84 results on '"Medica D"'

13. Extracranial Organ Dysfunction Due to Systemic Inflammation in Critically Ill Patients With Traumatic Brain Injury: A Potential Cause of Subclinical Acute Renal Damage in Kidney Transplantation Donors.

Author

Cantaluppi, V., primary, Civiletti, F., additional, Medica, D., additional, Mazzeo, A., additional, Assenzio, B., additional, Mastromauro, I., additional, Deambrosis, I., additional, Giaretta, F., additional, Fanelli, V., additional, and Mascia, L., additional

Published
2014
Full Text
View/download PDF

14. EXPERIMENTAL KIDNEY INJURY MECHANISMS

Author

Oliveira-Salles, E. B., primary, Maquigussa, E., additional, Semedo, P., additional, Pereira, L. G., additional, Ferreira, V. M., additional, Camara, N. O., additional, Bergamaschi, C. T., additional, Campos, R. R., additional, Boim, M. A., additional, Cantaluppi, V., additional, Medica, D., additional, Figliolini, F., additional, Quercia, A. D., additional, Dellepiane, S., additional, Virzi', G. M., additional, Ronco, C., additional, Tetta, C., additional, Biancone, L., additional, Camussi, G., additional, Wada, Y., additional, Iyoda, M., additional, Matsumoto, K., additional, Shindo-Hirai, Y., additional, Kuno, Y., additional, Suzuki, T., additional, Yamamoto, Y., additional, Saito, T., additional, Iseri, K., additional, Shibata, T., additional, Albertoni, G., additional, Reis, L. A., additional, Schor, N., additional, Fonseca, C. D., additional, Watanabe, M., additional, Mendonca, M. H., additional, Fernandes, S. M., additional, and Vattimo, M. D. F. F., additional

Published
2014
Full Text
View/download PDF

15. TRANSPLANTATION CLINICAL 1

Author

Schachtner, T., primary, Reinke, P., additional, Dorje, C., additional, Mjoen, G., additional, Midtvedt, K., additional, Strom, E. H., additional, Oyen, O., additional, Jenssen, T., additional, Reisaeter, A. V., additional, Smedbraaten, Y. V., additional, Sagedal, S., additional, Fagerland, M. W., additional, Hartmann, A., additional, Thiel, S., additional, Zulkarnaev, A., additional, Vatazin, A., additional, Vincenti, F., additional, Harel, E., additional, Kantor, A., additional, Thurison, T., additional, Hoyer-Hansen, G., additional, Craik, C., additional, Kute, V. B., additional, Shah, P. S., additional, Vanikar, A. V., additional, Modi, P. R., additional, Shah, P. R., additional, Gumber, M. R., additional, Patel, H. V., additional, Engineer, D. P., additional, Shah, V. R., additional, Rizvi, J., additional, Trivedi, H. L., additional, Malheiro, J., additional, Dias, L., additional, Martins, L. S., additional, Fonseca, I., additional, Pedroso, S., additional, Almeida, M., additional, Castro-Henriques, A., additional, Cabrita, A., additional, Costa, C., additional, Ritta, M., additional, Sinesi, F., additional, Sidoti, F., additional, Mantovani, S., additional, Di Nauta, A., additional, Messina, M., additional, Cavallo, R., additional, Verflova, A., additional, Svobodova, E., additional, Slatinska, J., additional, Slavcev, A., additional, Pokorna, E., additional, Viklicky, O., additional, Yagan, J., additional, Chandraker, A., additional, Diena, D., additional, Tognarelli, G., additional, Ranghino, A., additional, Bussolino, S., additional, Fop, F., additional, Segoloni, G. P., additional, Biancone, L., additional, Leone, F., additional, Mauro, M. V., additional, Gigliotti, P., additional, Lofaro, D., additional, Greco, F., additional, Perugini, D., additional, Papalia, T., additional, Perri, A., additional, Vizza, D., additional, Giraldi, C., additional, Bonofilgio, R., additional, Luis-Lima, S., additional, Marrero, D., additional, Gonzalez-Rinne, A., additional, Torres, A., additional, Salido, E., additional, Jimenez-Sosa, A., additional, Aldea-Perona, A., additional, Gonzalez-Posada, J. M., additional, Perez-Tamajon, L., additional, Rodriguez-Hernandez, A., additional, Negrin-Mena, N., additional, Porrini, E., additional, Pihlstrom, H., additional, Dahle, D. O., additional, Holdaas, H., additional, Von Der Lippe, N., additional, Waldum, B., additional, Brekke, F., additional, Amro, A., additional, Os, I., additional, Klin, P., additional, Sanabria, H., additional, Bridoux, P., additional, De Francesco, J., additional, Fortunato, R. M., additional, Raffaele, P., additional, Kong, J., additional, Son, S. H., additional, Kwon, H. Y., additional, Whang, E. J., additional, Choi, W. Y., additional, Yoon, C. S., additional, Thanaraj, V., additional, Theakstone, A., additional, Stopper, K., additional, Ferraro, A., additional, Bhattacharjya, S., additional, Devonald, M., additional, Williams, A., additional, Mella, A., additional, Gallo, E., additional, Di Vico, M. C., additional, Pagani, F., additional, Gai, M., additional, Cho, H. J., additional, Nho, K. W., additional, Park, S.-K., additional, Kim, S. B., additional, Yoshida, K., additional, Ishii, D., additional, Ohyama, T., additional, Kohguchi, D., additional, Takeuchi, Y., additional, Varga, A., additional, Sandor, B., additional, Kalmar-Nagy, K., additional, Toth, A., additional, Toth, K., additional, Szakaly, P., additional, Kildushevsky, A., additional, Fedulkina, V., additional, Kantaria, R., additional, Staeck, O., additional, Halleck, F., additional, Rissling, O., additional, Naik, M., additional, Neumayer, H.-H., additional, Budde, K., additional, Khadzhynov, D., additional, Bhadauria, D., additional, Kaul, A., additional, Prasad, N., additional, Sharma, R. K., additional, Sezer, S., additional, Bal, Z., additional, Erkmen Uyar, M., additional, Guliyev, O., additional, Erdemir, B., additional, Colak, T., additional, Ozdemir, N., additional, Haberal, M., additional, Caliskan, Y., additional, Yazici, H., additional, Artan, A. S., additional, Oto, O. A., additional, Aysuna, N., additional, Bozfakioglu, S., additional, Turkmen, A., additional, Yildiz, A., additional, Sever, M. S., additional, Yagisawa, T., additional, Nukui, A., additional, Kimura, T., additional, Nannmoku, K., additional, Kurosawa, A., additional, Sakuma, Y., additional, Miki, A., additional, Damiano, F., additional, Ligabue, G., additional, De Biasi, S., additional, Granito, M., additional, Cossarizza, A., additional, Cappelli, G., additional, Henriques, A. C., additional, Davide, J., additional, Von During, M. E., additional, Jenssen, T. G., additional, Bollerslev, J., additional, Godang, K., additional, Asberg, A., additional, Bachelet, T., additional, Martinez, C., additional, Bello, A., additional, Kejji, S., additional, Couzi, L., additional, Guidicelli, G., additional, Lepreux, S., additional, Visentin, J., additional, Congy-Jolivet, N., additional, Rostaing, L., additional, Taupin, J.-L., additional, Kamar, N., additional, Merville, P., additional, Ozdemir, H., additional, Yildirim, S., additional, Tutal, E., additional, Sayin, B., additional, Ozdemir Acar, N., additional, Banasik, M., additional, Boratynska, M., additional, Koscielska-Kasprzak, K., additional, Kaminska, D., additional, Bartoszek, D., additional, Mazanowska, O., additional, Krajewska, M., additional, Zmonarski, S., additional, Chudoba, P., additional, Dawiskiba, T., additional, Protasiewicz, M., additional, Halon, A., additional, Sas, A., additional, Kaminska, M., additional, Klinger, M., additional, Stefanovic, N., additional, Cvetkovic, T., additional, Velickovic - Radovanovic, R., additional, Jevtovic - Stoimenov, T., additional, Vlahovic, P., additional, Rungta, R., additional, Das, P., additional, Ray, D. S., additional, Gupta, S., additional, Kolonko, A., additional, Szotowska, M., additional, Kuczera, P., additional, Chudek, J., additional, Wiecek, A., additional, Sikora-Grabka, E., additional, Adamczak, M., additional, Madej, P., additional, Amanova, A., additional, Kendi Celebi, Z., additional, Bakar, F., additional, Caglayan, M. G., additional, Keven, K., additional, Massimetti, C., additional, Imperato, G., additional, Zampi, G., additional, De Vincenzi, A., additional, Fabbri, G. D. D., additional, Brescia, F., additional, Feriozzi, S., additional, Filipov, J. J., additional, Zlatkov, B. K., additional, Dimitrov, E. P., additional, Svinarov, D. A., additional, Poesen, R., additional, De Vusser, K., additional, Evenepoel, P., additional, Kuypers, D., additional, Naesens, M., additional, Meijers, B., additional, Kocak, H., additional, Yilmaz, V. T., additional, Yilmaz, F., additional, Uslu, H. B., additional, Aliosmanoglu, I., additional, Ermis, H., additional, Dinckan, A., additional, Cetinkaya, R., additional, Ersoy, F. F., additional, Suleymanlar, G., additional, Oliveira, J.-C., additional, Santos, J., additional, Lobato, L., additional, Mendonca, D., additional, Watarai, Y., additional, Yamamoto, T., additional, Tsujita, M., additional, Hiramitsu, T., additional, Goto, N., additional, Narumi, S., additional, Kobayashi, T., additional, Line, P.-D., additional, Housawi, A., additional, House, A., additional, Ng, C., additional, Denesyk, K., additional, Rehman, F., additional, Moist, L., additional, Musetti, C., additional, Battista, M., additional, Izzo, C., additional, Guglielmetti, G., additional, Airoldi, A., additional, Stratta, P., additional, Cena, T., additional, Quaglia, M., additional, Fenoglio, R., additional, Cagna, D., additional, Amoroso, A., additional, Palmisano, A., additional, Degli Antoni, A. M., additional, Vaglio, A., additional, Piotti, G., additional, Cremaschi, E., additional, Buzio, C., additional, Maggiore, U., additional, Lee, M.-C., additional, Hsu, B.-G., additional, Zalamea Jarrin, F., additional, Sanchez Sobrino, B., additional, Lafuente Covarrubias, O., additional, Karsten Alvarez, S., additional, Dominguez Apinaniz, P., additional, Llopez Carratala, R., additional, Portoles Perez, J., additional, Yildirim, T., additional, Yilmaz, R., additional, Turkmen, E., additional, Altindal, M., additional, Arici, M., additional, Altun, B., additional, Erdem, Y., additional, Dounousi, E., additional, Mitsis, M., additional, Naka, K., additional, Pappas, H., additional, Lakkas, L., additional, Harisis, H., additional, Pappas, K., additional, Koutlas, V., additional, Tzalavra, I., additional, Spanos, G., additional, Michalis, L., additional, Siamopoulos, K., additional, Iwabuchi, T., additional, Nanmoku, K., additional, Yasunaru, S., additional, Yoshikawa, M., additional, Kitamura, K., additional, Fuji, H., additional, Fujisawa, M., additional, Nishi, S., additional, Carta, P., additional, Zanazzi, M., additional, Buti, E., additional, Larti, A., additional, Caroti, L., additional, Di Maria, L., additional, Minetti, E. E., additional, Shi, Y., additional, Luo, L., additional, Cai, B., additional, Wang, T., additional, Zou, Y., additional, Wang, L., additional, Kim, Y., additional, Kim, H. S., additional, Choi, B. S., additional, Park, C. W., additional, Yang, C. W., additional, Kim, Y.-S., additional, Chung, B. H., additional, Baek, C. H., additional, Kim, M., additional, Kim, J.-S., additional, Yang, W. S., additional, Han, D. J., additional, Mikolasevic, I., additional, Racki, S., additional, Lukenda, V., additional, Persic, M. P., additional, Colic, M., additional, Devcic, B., additional, Orlic, L., additional, Gurlek Demirci, B., additional, Say N, C. B., additional, Ozdemir Acar, F. N., additional, Vali, S., additional, Ismal, K., additional, Sahay, M., additional, Civiletti, F., additional, Cantaluppi, V., additional, Medica, D., additional, Mazzeo, A. T., additional, Assenzio, B., additional, Mastromauro, I., additional, Deambrosis, I., additional, Giaretta, F., additional, Fanelli, V., additional, Mascia, L., additional, Gkirdis, I., additional, Bechlioulis, A., additional, Evangelou, D., additional, Zarzoulas, F., additional, Kotsia, A., additional, Balafa, O., additional, Tzeltzes, G., additional, Nakas, G., additional, Kalaitzidis, R., additional, Katsouras, C., additional, Uyanik, S., additional, Toprak, S. K., additional, Ilhan, O., additional, Ekmen Uyar, M., additional, Hernandez Vargas, H., additional, Artamendi Larranaga, M., additional, Ramalle Gomara, E., additional, Gil Catalinas, F., additional, Bello Ovalle, A., additional, Pimentel Guzman, G., additional, Coloma Lopez, A., additional, Sierra Carpio, M., additional, Gil Paraiso, A., additional, Dall Anesse, C., additional, Beired Val, I., additional, Huarte Loza, E., additional, Choy, B. Y., additional, Kwan, L., additional, Mok, M., additional, Chan, T. M., additional, Yamakawa, T., additional, Kobayashi, A., additional, Yamamoto, I., additional, Mafune, A., additional, Nakada, Y., additional, Tannno, Y., additional, Tsuboi, N., additional, Yamamoto, H., additional, Yokoyama, K., additional, Ohkido, I., additional, Yokoo, T., additional, Luque, Y., additional, Anglicheau, D., additional, Rabant, M., additional, Clement, R., additional, Kreis, H., additional, Sartorius, A., additional, Noel, L.-H., additional, Timsit, M.-O., additional, Legendre, C., additional, Rancic, N., additional, Vavic, N., additional, Dragojevic-Simic, V., additional, Katic, J., additional, Jacimovic, N., additional, Kovacevic, A., additional, Mikov, M., additional, Veldhuijzen, N. M. H., additional, Rookmaaker, M. B., additional, Van Zuilen, A. D., additional, Nquyen, T. Q., additional, Boer, W. H., additional, Sahtout, W., additional, Ghezaiel, H., additional, Azzebi, A., additional, Ben Abdelkrim, S., additional, Guedri, Y., additional, Mrabet, S., additional, Nouira, S., additional, Ferdaws, S., additional, Amor, S., additional, Belarbia, A., additional, Zellama, D., additional, Mokni, M., additional, Achour, A., additional, Parikova, A., additional, Hanzal, V., additional, Fronek, J., additional, Orandi, B. J., additional, James, N. T., additional, Montgomery, R. A., additional, Desai, N. M., additional, Segev, D. L., additional, Fontana, F., additional, Ballestri, M., additional, and Magistroni, R., additional

Published
2014
Full Text
View/download PDF

16. Diabetes - experimental models

Author

Blanco-Gozalo, V., primary, Blazquez-Medela, A., additional, Garcia-Sanchez, O., additional, Quiros, Y., additional, Montero, M., additional, Martinez-Salgado, C., additional, Lopez-Hernandez, F., additional, Lopez-Novoa, J., additional, Yao, L., additional, Qing, Z., additional, Hua, X., additional, Min, F., additional, Fei, M., additional, Ning, W., additional, Cantaluppi, V., additional, Figliolini, F., additional, Delena, M., additional, Beltramo, S., additional, Medica, D., additional, Tetta, C., additional, Segoloni, G., additional, Biancone, L., additional, Camussi, G., additional, Cunha, J. S., additional, Ferreira, V. M., additional, Naves, M. A., additional, Boim, M. A., additional, Zitman-Gal, T., additional, Golan, E., additional, Green, J., additional, Pasmanik-Chor, M., additional, Bernheim, J., additional, Benchetrit, S., additional, Riera, M., additional, Clotet, S., additional, Pascual, J., additional, Soler, M., additional, Nakai, K., additional, Fujii, H., additional, Kono, K., additional, Goto, S., additional, Hirata, M., additional, Shinohara, M., additional, Fukagawa, M., additional, Nishi, S., additional, Fan, Q., additional, Du, S., additional, Jiang, Y., additional, Wang, L., additional, Fang, L., additional, Radovits, T., additional, Mozes, M. M., additional, Rosivall, L., additional, Kokeny, G., additional, Aoki, R., additional, Tateoka, R., additional, Sekine, F., additional, Kikuchi, K., additional, Yamashita, Y., additional, Itoh, Y., additional, Cappuccino, L., additional, Garibotto, G., additional, D'Amato, E., additional, Villaggio, B., additional, Gianiorio, F., additional, Mij, M., additional, Viazzi, F., additional, Salvidio, G., additional, Verzola, D., additional, Piwkowska, A., additional, Rogacka, D., additional, Audzeyenka, I., additional, Kasztan, M., additional, Angielski, S., additional, Jankowski, M., additional, Gaber, E. W., additional, El-Attar, H. A., additional, Liu, J., additional, Zhang, W., additional, He, Y., additional, Macsai, E., additional, Takats, Z., additional, Derzbach, L., additional, Korner, A., additional, Vasarhelyi, B., additional, Huang, M. S., additional, Bo, H., additional, Liu, F., additional, Fu, P., additional, Tsotakos, N. E., additional, Tsilibary, E. C., additional, Drossopoulou, G. I., additional, Thawho, N., additional, Farid, N., additional, Peleg, A., additional, Levy, A., additional, Nakhoul, N., additional, Lenghel, A. R., additional, Borza, G., additional, Catoi, C., additional, Bondor, C. I., additional, Muresan, A., additional, Kacso, I. M., additional, Song, J.-S., additional, Song, J.-H., additional, Ahn, S.-H., additional, Choi, B. S., additional, Hong, Y. a., additional, Kim, M. Y., additional, Lim, J. H., additional, Yang, K.-S., additional, Chung, S., additional, Shin, S. J., additional, Kim, H. W., additional, Chang, Y. S., additional, Kim, Y. S., additional, Park, C. W., additional, Takayanagi, K., additional, Hasegawa, H., additional, Shimizu, T., additional, Ikari, A., additional, Noiri, C., additional, Iwashita, T., additional, Tayama, Y., additional, Asakura, J., additional, Anzai, N., additional, Kanozawa, K., additional, Kato, H., additional, Mitarai, T., additional, Huang, M., additional, Ashour, R. H., additional, Fouda, A. E.-M. M., additional, Saad, M. A., additional, El-Banna, F. M., additional, Moustafa, F. A., additional, Fouda, M. I., additional, Sanchez-Nino, M. D., additional, Sanz, A. B., additional, Poveda, J., additional, Saleem, M., additional, Mathieson, P., additional, Ruiz-Ortega, M., additional, Selgas, R., additional, Egido, J., additional, Ortiz, A., additional, Soler, M. J., additional, Rebull, M., additional, Marquez, E., additional, Okazaki, S., additional, Kogure, Y., additional, Sano, T., additional, Hatano, M., additional, Kreft, E., additional, Kowalski, R., additional, Szczepansk-Konkel, M., additional, Liu, X., additional, Yang, G., additional, Osman, N. A., additional, NasrAllah, M. M., additional, Kamal, M. M., additional, Ahmed, A. I., additional, Fekih-Mrissa, N., additional, Mrad, M., additional, Baffoun, A., additional, Sayeh, A., additional, Hmida, J., additional, Gritli, N., additional, Galchinskaya, V., additional, Topchii, I., additional, Semenovykh, P., additional, Yefimova, N., additional, Zheng, D., additional, Hu, D., additional, Li, X., additional, Peng, A. I., additional, Olea-Herrero, N., additional, Arenas, M., additional, Munoz-Moreno, C., additional, Moreno-Gomez-Toledano, R., additional, Gonzalez-Santander, M., additional, Arribas, I., additional, and Bosch, R., additional

Published
2013
Full Text
View/download PDF

17. Tubular ischemia and toxicity

Author

Cantaluppi, V., primary, Medica, D., additional, Figliolini, F., additional, Gatti, S., additional, Bruno, S., additional, Quercia, A. D., additional, Dellepiane, S., additional, Biancone, L., additional, Tetta, C., additional, Camussi, G., additional, Zhou, L., additional, Dai, X., additional, Feng, M., additional, Huang, X., additional, Fu, P., additional, Lan, H. Y., additional, de Ramon, L., additional, Ripoll, E., additional, Luzardo, L., additional, Merino, A., additional, Bolanos, N., additional, Lloberas, N., additional, Cruzado, J. M., additional, Grinyo, J. M., additional, Torras, J., additional, Kaucsar, T., additional, Revesz, C., additional, Godo, M., additional, Racz, Z., additional, Tarszabo, R., additional, Hamar, P., additional, Banki, N. F., additional, Hosszu, A., additional, Antal, Z., additional, Koszegi, S., additional, Wagner, L., additional, Gellai, R., additional, Lenart, L., additional, Vannay, A., additional, Muller, V., additional, Szabo, A. J., additional, Tulassay, T., additional, and Fekete, A., additional

Published
2013
Full Text
View/download PDF

18. Glomerular injury

Author

Djudjaj, S., primary, Lue, H., additional, Urzinicok, T., additional, Engel, D., additional, Martin, I. V., additional, Buhl, E. M., additional, Floege, J., additional, Ostendorf, T., additional, Bernhagen, J., additional, Boor, P., additional, Cantaluppi, V., additional, Medica, D., additional, Mannari, C., additional, Figliolini, F., additional, Migliori, M., additional, Panichi, V., additional, Tetta, C., additional, Camussi, G., additional, Schulte, K., additional, Berger, K., additional, Sicking, E. M., additional, Jirak, P., additional, Thevissen, L., additional, Fuss, A., additional, Kriz, W., additional, Smeets, B., additional, Moeller, M. J., additional, Santhosh Kumar, V. R., additional, Kulkarni, O. P., additional, Darisipudi, N. M., additional, Mulay, S. R., additional, Anders, H.-J., additional, Assady, S., additional, Alter, J., additional, Litvak, M., additional, Ilan, N., additional, Vlodavsky, I., additional, and Abassi, Z., additional

Published
2013
Full Text
View/download PDF

19. Kidney in sepsis

Author

Fortrie, G., primary, de Geus, H. R., additional, Betjes, M. G., additional, van Schaik, R. H., additional, Groeneveld, J., additional, Cantaluppi, V., additional, Figliolini, F., additional, Medica, D., additional, Quercia, A. D., additional, Inguaggiato, P., additional, Pacitti, A., additional, Camussi, G., additional, and Tetta, C., additional

Published
2013
Full Text
View/download PDF

20. Microvesicles Derived from Endothelial Progenitor Cells (EPCs) Protect from Antibody- and Complement-Mediated Endothelial Injury by Horizontal Transfer of Specific mRNAs and MicroRNAs: Potential Role in Graft Accomodation

Author

Cantaluppi, V., primary, Delena, M., additional, Beltramo, S., additional, Figliolini, F., additional, Medica, D., additional, Randone, O., additional, Gallo, E., additional, Tognarelli, G., additional, Biancone, L., additional, Segoloni, G. P., additional, and Camussi, G., additional

Published
2012
Full Text
View/download PDF

22. Plasma NGAL Is An Early Biomarker of Graft Function, Calcineurin Inhibitor Nephrotoxicity and Tubular Regeneration in Kidney Transplantation from Extended Criteria Donors

Author

Cantaluppi, V., primary, Tamagnone, M., additional, Dellepiane, S., additional, Medica, D., additional, Manzione, A. M., additional, Messina, M., additional, Figliolini, F., additional, Ranghino, A., additional, Biancone, L., additional, Camussi, G., additional, and Segoloni, G. P., additional

Published
2012
Full Text
View/download PDF

23. Experimental pathology

Author

Yi Chun, D. X., primary, Alexandre, H., additional, Edith, B., additional, Nacera, O., additional, Julie, P., additional, Chantal, J., additional, Eric, R., additional, Zhang, X., additional, Jin, Y., additional, Miravete, M., additional, Dissard, R., additional, Klein, J., additional, Gonzalez, J., additional, Caubet, C., additional, Pecher, C., additional, Pipy, B., additional, Bascands, J.-L., additional, Mercier-Bonin, M., additional, Schanstra, J., additional, Buffin-Meyer, B., additional, Claire, R., additional, Rigothier, C., additional, Richard, D., additional, Sebastien, L., additional, Moin, S., additional, Chantal, B., additional, Christian, C., additional, Jean, R., additional, Migliori, M., additional, Cantaluppi, V., additional, Mannari, C., additional, Medica, D., additional, Giovannini, L., additional, Panichi, V., additional, Goldwich, A., additional, Alexander, S., additional, Andre, G., additional, Amann, K., additional, Migliorini, A., additional, Sagrinati, C., additional, Angelotti, M. L., additional, Mulay, S. R., additional, Ronconi, E., additional, Peired, A., additional, Romagnani, P., additional, Anders, H.-J., additional, Chiang, W. C., additional, Lai, C. F., additional, Peng, W.-H., additional, Wu, C. F., additional, Chang, F.-C., additional, Chen, Y.-T., additional, Lin, S.-L., additional, Chen, Y. M., additional, Wu, K. D., additional, Lu, K.-S., additional, Tsai, T. J., additional, Virgine, O., additional, Qing Feng, F., additional, Zhang, S.-Y., additional, Dominique, D., additional, Vincent, A., additional, Marina, C., additional, Philippe, L., additional, Georges, G., additional, Pawlak, A., additional, Sahali, D., additional, Matsumoto, S., additional, Kiyomoto, H., additional, Ichimura, A., additional, Dan, T., additional, Nakamichi, T., additional, Tsujita, T., additional, Akahori, K., additional, Ito, S., additional, Miyata, T., additional, Xie, S., additional, Zhang, B., additional, Shi, W., additional, Yang, Y., additional, Nagasu, H., additional, Satoh, M., additional, Kidokoro, K., additional, Nishi, Y., additional, Ihoriya, C., additional, Kadoya, H., additional, Sasaki, T., additional, Kashihara, N., additional, Wu, C.-F., additional, Chou, Y.-H., additional, Duffield, J., additional, Rocca, C., additional, Gregorini, M., additional, Corradetti, V., additional, Valsania, T., additional, Bedino, G., additional, Bosio, F., additional, Pattonieri, E. F., additional, Esposito, P., additional, Sepe, V., additional, Libetta, C., additional, Rampino, T., additional, Dal Canton, A., additional, Omori, H., additional, Kawada, N., additional, Inoue, K., additional, Ueda, Y., additional, Yamamoto, R., additional, Matsui, I., additional, Kaimori, J., additional, Takabatake, Y., additional, Moriyama, T., additional, Isaka, Y., additional, Rakugi, H., additional, Wasilewska, A., additional, Taranta-Janusz, K., additional, Deebek, W., additional, Kuroczycka-Saniutycz, E., additional, Lee, A. S., additional, Lee, J. E., additional, Jung, Y. J., additional, Kang, K. P., additional, Lee, S., additional, Kim, W., additional, Arfian, N., additional, Emoto, N., additional, Yagi, K., additional, Nakayama, K., additional, Hartopo, A. B., additional, Nugrahaningsih, D. A., additional, Yanagisawa, M., additional, Hirata, K.-I., additional, Munoz-Felix, J. M., additional, Lopez-Novoa, J. M., additional, Martinez-Salgado, C., additional, Oujo, B., additional, Arevalo, M., additional, Bernabeu, C., additional, Perez-Barriocanal, F., additional, Jesper, K., additional, Nathalie, V., additional, Pierre, G., additional, Yi Chun, D. X., additional, Iyoda, M., additional, Shibata, T., additional, Matsumoto, K., additional, Shindo-Hirai, Y., additional, Kuno, Y., additional, Wada, Y., additional, Akizawa, T., additional, Schwartz, I., additional, Schwartz, D., additional, Prot Bertoye, C., additional, Terryn, S., additional, Claver, J., additional, Beghdadi, W. B., additional, Monteiro, R., additional, Blank, U., additional, Devuyst, O., additional, Daugas, E., additional, Van Beneden, K., additional, Geers, C., additional, Pauwels, M., additional, Mannaerts, I., additional, Van den Branden, C., additional, Van Grunsven, L. A., additional, Seckin, I., additional, Pekpak, M., additional, Uzunalan, M., additional, Uruluer, B., additional, Kokturk, S., additional, Ozturk, Z., additional, Sonmez, H., additional, Yaprak, E., additional, Furuno, Y., additional, Tsutsui, M., additional, Morishita, T., additional, Shimokawa, H., additional, Otsuji, Y., additional, Yanagihara, N., additional, Kabashima, N., additional, Ryota, S., additional, Kanegae, K., additional, Miyamoto, T., additional, Nakamata, J., additional, Ishimatsu, N., additional, Tamura, M., additional, Nakagawa, T., additional, Ichikawa, K., additional, Miyamoto, M., additional, Takabayashi, D., additional, Yamazaki, H., additional, Kakeshita, K., additional, Koike, T., additional, Kagitani, S., additional, Tomoda, F., additional, Hamashima, T., additional, Ishii, Y., additional, Inoue, H., additional, Sasahara, M., additional, El Machhour, F., additional, Kerroch, M., additional, Mesnard, L., additional, Chatziantoniou, C., additional, Dussaule, J.-C., additional, Inui, K., additional, Sasai, F., additional, Maruta, Y., additional, Nishiwaki, H., additional, Kawashima, E., additional, Inoue, Y., additional, Yoshimura, A., additional, Musacchio, E., additional, Priante, G., additional, Valvason, C., additional, Sartori, L., additional, Baggio, B., additional, Kim, J. H., additional, Gross, O., additional, Diana, R., additional, Gry, D. H., additional, Asimal, B., additional, Johanna, T., additional, Imke, S.-E., additional, Lydia, W., additional, Gerhard-Anton, M., additional, Hassan, D., additional, Cano, J. L., additional, Griera, M., additional, Olmos, G., additional, Martin, P., additional, Cortes, M. A., additional, Lopez-Ongil, S., additional, Rodriguez-Puyol, D., additional, DE Frutos, S., additional, Gonzalez, M., additional, Luengo, A., additional, Rodriguez-Puyol, M., additional, Calleros, L., additional, Lupica, R., additional, Lacquaniti, A., additional, Donato, V., additional, Maggio, R., additional, Mastroeni, C., additional, Lucisano, S., additional, Cernaro, V., additional, Fazio, M. R., additional, Quartarone, A., additional, Buemi, M., additional, Kacik, M., additional, Goedicke, S., additional, Eggert, H., additional, Hoyer, J. D., additional, Wurm, S., additional, Steege, A., additional, Banas, M., additional, Kurtz, A., additional, Banas, B., additional, Lasagni, L., additional, Lazzeri, E., additional, Romoli, S., additional, Schaefer, I., additional, Teng, B., additional, Worthmann, K., additional, Haller, H., additional, Schiffer, M., additional, Prattichizzo, C., additional, Netti, G. S., additional, Rocchetti, M. T., additional, Cormio, L., additional, Carrieri, G., additional, Stallone, G., additional, Grandaliano, G., additional, Ranieri, E., additional, Gesualdo, L., additional, Kucher, A., additional, Smirnov, A., additional, Parastayeva, M., additional, Beresneva, O., additional, Kayukov, I., additional, Zubina, I., additional, Ivanova, G., additional, Abed, A., additional, Schlekenbach, L., additional, Foglia, B., additional, Kwak, B., additional, Chadjichristos, C., additional, Queisser, N., additional, Schupp, N., additional, Brand, S., additional, Himer, L., additional, Szebeni, B., additional, Sziksz, E., additional, Saijo, S., additional, Kis, E., additional, Prokai, A., additional, Banki, N. F., additional, Fekete, A., additional, Tulassay, T., additional, Vannay, A., additional, Hegner, B., additional, Schaub, T., additional, Lange, C., additional, Dragun, D., additional, Klinkhammer, B. M., additional, Rafael, K., additional, Monika, M., additional, Anna, M., additional, Van Roeyen, C., additional, Boor, P., additional, Eva Bettina, B., additional, Simon, O., additional, Esther, S., additional, Floege, J., additional, Kunter, U., additional, Janke, D., additional, Jankowski, J., additional, Hayashi, M., additional, Takamatsu, I., additional, Horimai, C., additional, Yoshida, T., additional, Seno DI Marco, G., additional, Koenig, M., additional, Stock, C., additional, Reiermann, S., additional, Amler, S., additional, Koehler, G., additional, Fobker, M., additional, Buck, F., additional, Pavenstaedt, H., additional, Lang, D., additional, Brand, M., additional, Plotnikov, E., additional, Morosanova, M., additional, Pevzner, I., additional, Zorova, L., additional, Pulkova, N., additional, Zorov, D., additional, Wornle, M., additional, Ribeiro, A., additional, Belling, F., additional, Merkle, M., additional, Nakazawa, D., additional, Nishio, S., additional, Shibasaki, S., additional, Tomaru, U., additional, Akihiro, I., additional, Kobayashi, I., additional, Imanishi, Y., additional, Kurajoh, M., additional, Nagata, Y., additional, Yamagata, M., additional, Emoto, M., additional, Michigami, T., additional, Ishimura, E., additional, Inaba, M., additional, Wu, C.-C., additional, Lu, K.-C., additional, Chen, J.-S., additional, Chu, P., additional, Lin, Y.-F., additional, Eller, K., additional, Schroll, A., additional, Kirsch, A., additional, Huber, J., additional, Weiss, G., additional, Theurl, I., additional, Rosenkranz, A. R., additional, Zawada, A., additional, Rogacev, K., additional, Achenbach, M., additional, Fliser, D., additional, Held, G., additional, Heine, G. H., additional, Miyamoto, Y., additional, Iwao, Y., additional, Watanabe, H., additional, Kadowaki, D., additional, Ishima, Y., additional, Chuang, V. T. G., additional, Sato, K., additional, Otagiri, M., additional, Maruyama, T., additional, Iwatani, H., additional, Honda, D., additional, Noguchi, T., additional, Tanaka, M., additional, Tanaka, H., additional, Fukagawa, M., additional, Pircher, J., additional, Koppel, S., additional, Mannell, H., additional, Krotz, F., additional, Virzi, G. M., additional, Bolin, C., additional, Cruz, D., additional, Scalzotto, E., additional, De Cal, M., additional, Vescovo, G., additional, Ronco, C., additional, Grobmayr, R., additional, Lech, M., additional, Ryu, M., additional, Aoshima, Y., additional, Mizobuchi, M., additional, Ogata, H., additional, Kumata, C., additional, Nakazawa, A., additional, Kondo, F., additional, Ono, N., additional, Koiwa, F., additional, Kinugasa, E., additional, Freisinger, W., additional, Lale, N., additional, Lampert, A., additional, Ditting, T., additional, Heinlein, S., additional, Schmieder, R. E., additional, Veelken, R., additional, Nave, H., additional, Perthel, R., additional, Suntharalingam, M., additional, Bode-Boger, S., additional, Beutel, G., additional, Kielstein, J., additional, Rodrigues-Diez, R., additional, Rayego-Mateos, S., additional, Lavoz, C., additional, Stark Aroeira, L. G., additional, Orejudo, M., additional, Alique, M., additional, Ortiz, A., additional, Egido, J., additional, Ruiz-Ortega, M., additional, Oskar, W., additional, Rusan, C., additional, Padberg, J.-S., additional, Wiesinger, A., additional, Reuter, S., additional, Grabner, A., additional, Kentrup, D., additional, Lukasz, A., additional, Oberleithner, H., additional, Pavenstadt, H., additional, Kumpers, P., additional, Eberhardt, H. U., additional, Skerka, C., additional, Chen, Q., additional, Hallstroem, T., additional, Hartmann, A., additional, Kemper, M. J., additional, Zipfel, P. F., additional, N'gome-Sendeyo, K., additional, Fan, Q.-F., additional, Toblli, J., additional, Cao, G., additional, Giani, J. F., additional, Dominici, F. P., additional, Kim, J. S., additional, Yang, J. W., additional, Kim, M. K., additional, Han, B. G., additional, and Choi, S. O., additional

Published
2012
Full Text
View/download PDF

24. AKI and stem cells

Author

Simone, S., primary, Cariello, M., additional, Cosola, C., additional, Sallustio, F., additional, Loverre, A., additional, Schena, F. P., additional, Grandaliano, G., additional, Gesualdo, L., additional, Pertosa, G., additional, Castellano, G., additional, Curci, C., additional, Stasi, A., additional, Simone, S., additional, Montinaro, V., additional, Ditonno, P., additional, Battaglia, M., additional, Staffieri, F., additional, Crovace, A., additional, Oortwjin, B., additional, Van Amersfoort, E., additional, Weissgarten, J., additional, Efrati, S., additional, Berman, S., additional, Abu Hamad, R., additional, Christo, J. S., additional, Aparecida Reis, L., additional, Borges, F., additional, Simoes, M. d. J., additional, Schor, N., additional, Cantaluppi, V., additional, Bruno, S., additional, Figliolini, F., additional, Medica, D., additional, Tetta, C., additional, and Camussi, G., additional

Published
2012
Full Text
View/download PDF

25. Transplantation - basic

Author

Adamczak, M., primary, Koleganova, N., additional, Nyengaard, J. R., additional, Ritz, E., additional, Wiecek, A., additional, Slabiak Blaz, N., additional, Yi Chun, D. X., additional, Alexandre, H., additional, Sandrine, G.-S., additional, Olivier, T., additional, Isabelle, E., additional, Christophe, L., additional, Guy, T., additional, Pierre Francois, W., additional, Jean-Philippe, R., additional, Yvon, L., additional, Eric, R., additional, Muller-Krebs, S., additional, Weber, L., additional, Tsobaneli, J., additional, Reiser, J., additional, Zeier, M., additional, Schwenger, V., additional, Tinel, C., additional, Samson, M., additional, Bonnotte, B., additional, Mousson, C., additional, Machcinska, M., additional, Bocian, K., additional, Wyzgal, M., additional, Korczak-Kowalska, G., additional, Ju, M. K., additional, Huh, K. H., additional, Park, K. T., additional, Kim, S. J., additional, Cho, B. H., additional, Kim, C. D., additional, So, B. J., additional, Leee, S., additional, Kang, C. M., additional, Joo, D. J., additional, Kim, Y. S., additional, Zarzycki, M., additional, Sobich, A., additional, Matsuyama, M., additional, Hase, T., additional, Yoshimura, R., additional, Koshino, K., additional, Sakai, K., additional, Suzuki, T., additional, Nobori, S., additional, Ushigome, H., additional, Brikci-Nigassa, L., additional, Chargui, J., additional, Touraine, J.-L., additional, Yoshimura, N., additional, Cantaluppi, V., additional, Medica, D., additional, Figliolini, F., additional, Migliori, M., additional, Mannari, C., additional, Dellepiane, S., additional, Quercia, A. D., additional, Randone, O., additional, Tamagnone, M., additional, Messina, M., additional, Manzione, A. M., additional, Ranghino, A., additional, Biancone, L., additional, Segoloni, G. P., additional, Camussi, G., additional, Turk, T. R., additional, Zou, X., additional, Rauen, U., additional, De Groot, H., additional, Amann, K., additional, Kribben, A., additional, Eckardt, K.-U., additional, Bernhardt, W. M., additional, Witzke, O., additional, Lidia, G., additional, Wouter, C., additional, Eric, A., additional, Yann, L. M., additional, Christian, N., additional, Marie, E., additional, Pierre, M., additional, Zineb, A., additional, Miriana, D., additional, Annick, M., additional, Marc, A., additional, Daniel, A., additional, Wornle, M., additional, Ribeiro, A., additional, Motamedi, N., additional, Grone, H. J., additional, Cohen, C. D., additional, Schlondorff, D., additional, Schmid, H., additional, Teplan, V., additional, Banas, M., additional, Banas, B., additional, Steege, A., additional, Bergler, T., additional, Kruger, B., additional, Schnulle, P., additional, Yard, B., additional, Kramer, B. K., additional, Hoger, S., additional, Xavier, M. P., additional, Sampaio-Norton, S., additional, Gaiao, S., additional, Alves, H., additional, Oliveira, G., additional, Zaza, G., additional, Rascio, F., additional, Pontrelli, P., additional, Granata, S., additional, Rugiu, C., additional, Grandaliano, G., additional, Lupo, A., additional, Wohlfahrtova, M., additional, Brabcova, I., additional, Balaz, P., additional, Janousek, L., additional, Lodererova, A., additional, Honsova, E., additional, Wohlfahrt, P., additional, Viklicky, O., additional, Grabner, A., additional, Kentrup, D., additional, Edemir, B., additional, Sirin, Y., additional, Pavenstadt, H., additional, Schober, O., additional, Schlatter, E., additional, Schafers, M., additional, Schnockel, U., additional, Reuter, S., additional, Accetturo, M., additional, Gigante, M., additional, Tataranni, T., additional, Zito, A., additional, Schena, A., additional, Schena, F. P., additional, Stallone, G., additional, Gesualdo, L., additional, Maillard, N., additional, Masson, I., additional, Lena, A., additional, Manolie, M., additional, Christophe, M., additional, Lassen, C. K., additional, Keller, A. K., additional, Moldrup, U., additional, Bibby, B. M., additional, Jespersen, B., additional, Cvetkovic, T., additional, Velickovic Radovanovic, R., additional, Pavlovic, R., additional, Djordjevic, V., additional, Vlahovic, P., additional, Stefanovic, N., additional, Sladojevic, N., additional, Ignjatovic, A., additional, Rong, S., additional, Menne, J., additional, Haller, H., additional, Suszdak, P., additional, Tomczuk, P., additional, Gueler, F., additional, Nelli, S., additional, Sara, D., additional, Salma, E. K., additional, Naoufal, M., additional, Tarik, M., additional, Mohamed, Z., additional, Guislaine, M., additional, Mohamed Gharbi, B., additional, Benyounes, R., additional, Lu, X., additional, Shushakova, N., additional, Kirsch, T., additional, Bockmeyer, C. L., additional, Ramackers, W., additional, Wittig, J., additional, Agustian, P. A., additional, Klose, J., additional, Dammrich, M. E., additional, Kreipe, H., additional, Brocker, V., additional, Winkler, M., additional, and Becker, J. U., additional

Published
2012
Full Text
View/download PDF

26. Transplantation basic

Author

Cantaluppi, V., primary, De Lena, M., additional, Figliolini, F., additional, Beltramo, S., additional, Medica, D., additional, Tognarelli, G., additional, Biancone, L., additional, Tetta, C., additional, Segoloni, G. P., additional, Camussi, G., additional, Pontrelli, P., additional, Cariello, M., additional, Verrienti, R., additional, Tataranni, T., additional, Gigante, M., additional, Loverre, A., additional, Stallone, G., additional, Schena, F. P., additional, Ranieri, E., additional, Gesualdo, L., additional, Grandaliano, G., additional, Coupel, S., additional, Charreau, B., additional, Canet, E., additional, Gerard, N., additional, Segalen, I., additional, Alexandre, N., additional, Grall, A., additional, Jacques-Olivier, P., additional, Hillion, S., additional, Le Meur, Y., additional, Alexandre, H., additional, Dany, A., additional, Michel, D., additional, Denis, G., additional, Christophe, L., additional, Nacera, O., additional, Isabelle, B., additional, Eric, R., additional, Yi Chun, D. X., additional, Buob, D., additional, Grimbert, P., additional, Glowacki, F., additional, Labalette, M., additional, Dufosse, F., additional, Nochy, D., additional, Copin, M.-C., additional, Boleslawski, E., additional, Noel, C., additional, and Hazzan, M., additional

Published
2012
Full Text
View/download PDF

27. AKI - Experimental

Author

Kaynar, K., primary, Kaynar, K., additional, Ersoz, S., additional, Aliyazioglu, R., additional, Uzun, A., additional, Ulusoy, S., additional, Al, S., additional, Ozkan, G., additional, Cansiz, M., additional, Bertocchio, J.-P., additional, Lancon, J., additional, El Moghrabi, S., additional, Galmiche, G., additional, Duong Van Huyen, J.-P., additional, Rieu, P., additional, Jaisser, F., additional, Albertoni, G., additional, Andrade, S., additional, Barreto, J. A., additional, Borges, F., additional, Schor, N., additional, Ho, W.-Y., additional, Chen, S.-H., additional, Tseng, C.-J., additional, Bienholz, A., additional, Feldkamp, T., additional, Weinberg, J. M., additional, Suller Garcia, J., additional, Naves, M., additional, Aparecida Reis, L., additional, Simoes, M. d. J., additional, S Almeida, W., additional, Moreau Longo, V., additional, Segreto, H. R. C., additional, Ghoneim, A., additional, Elkholy, A., additional, Medhat Abbas, T., additional, El Hadeedy, M., additional, Elhusseini, F., additional, Elessawey, B., additional, Eltanaihy, E., additional, Lotfy, A., additional, Eldesoky, S., additional, Sheashaa, H., additional, Sobh, M., additional, Minning, D. M., additional, Warnock, D., additional, Mohamed, A. S., additional, Wirthlin, J. B., additional, Chintalacharuvu, S. R., additional, Boone, L., additional, Brenner, R. M., additional, Santina Christo, J., additional, Dos Santos Passos, C., additional, Rene de Alencar, D., additional, De Braganca, A. C., additional, Canale, D., additional, Goncalves, J. G., additional, Brandao, T. P. B., additional, Shimizu, M. H. M., additional, Volpini, R. A., additional, Seguro, A. C., additional, Andrade, L., additional, Lee, J.-W., additional, Kim, H. K., additional, Cho, W. Y., additional, Jo, S.-K., additional, Cho, E., additional, Hocherl, K., additional, Schmidt, C., additional, Mulay, S. R., additional, Kulkarni, O. P., additional, Rupanagudi, K. V., additional, Migliorini, A., additional, Liapis, H., additional, Anders, H.-J., additional, Pevzner, I., additional, Chupyrkina, A., additional, Plotnikov, E., additional, Zorov, D., additional, Lopez-Novoa, J.-M., additional, Eleno, N., additional, Perez-Barriocanal, F., additional, Arevalo, M., additional, Docherty, N., additional, Castellano, G., additional, Divella, C., additional, Loverre, A., additional, Stasi, A., additional, Curci, C., additional, Rossini, M., additional, Ditonno, P., additional, Battaglia, M., additional, Daha, M. R., additional, Van Kooten, C., additional, Gesualdo, L., additional, Schena, F. P., additional, Grandaliano, G., additional, Tsuda, H., additional, Kawada, N., additional, Iwatani, H., additional, Moriyama, T., additional, Takahara, S., additional, Rakugi, H., additional, Isaka, Y., additional, Schley, G., additional, Kalucka, J., additional, Klanke, B., additional, Jantsch, J., additional, Olbrich, S., additional, Baumgartl, J., additional, Amann, K., additional, Eckardt, K.-U., additional, Weidemann, A., additional, Dolgolikova, A., additional, Pilotovich, V., additional, Ivanchik, G., additional, Shved, I., additional, Banki, N. F., additional, Antal, Z., additional, Hosszu, A., additional, Koszegi, S., additional, Vannay, A., additional, Wagner, L., additional, Prokai, A., additional, Muller, V., additional, Szabo, A. J., additional, Fekete, A., additional, Farrag, S., additional, Abulasrar, S., additional, Salama, , M., additional, Amin, M., additional, Ali, A., additional, Rubera, I., additional, Duranton, C., additional, Cougnon, M., additional, Melis, N., additional, Tauc, M., additional, Jankauskas, S., additional, Morosanova, M., additional, Pulkina, N., additional, Zorova, L., additional, Shin, Y. T., additional, Kim, S. S., additional, Chang, Y. K., additional, Choi, D. E., additional, Na, K.-R., additional, Lee, K. W., additional, Choi, J.-Y., additional, Jin, D.-C., additional, Cha, J.-H., additional, Schneider, R., additional, Betz, B., additional, Meusel, M., additional, Held, C., additional, Wanner, C., additional, Gekle, M., additional, Sauvant, C., additional, Pisani, A., additional, Rossano, R., additional, Mancini, A., additional, Arfian, N., additional, Yagi, K., additional, Nakayama, K., additional, Ali, H., additional, Mayasari, D. S., additional, Purnomo, E., additional, Emoto, N., additional, Efrati, S., additional, Berman, S., additional, Abu Hamad, R., additional, Weissgarten, J., additional, Scherbaum, C. R., additional, Allam, R., additional, Lichtnekert, J., additional, Darisipudi, M. N., additional, Hagele, H., additional, Hohenstein, B., additional, Hugo, C., additional, Schaefer, L., additional, Corsi, C., additional, Ferramosca, E., additional, Grandi, E., additional, Pisoni, L., additional, Rivolta, I., additional, Dalpozzo, B., additional, Hoxha, E., additional, Severi, S., additional, Santoro, A., additional, Laurent, M., additional, Cedric, R., additional, Dominique, C., additional, Sophie, V., additional, Nochy, D., additional, Loic, G., additional, Patrice, C., additional, Chantal, J., additional, Marie-Christine, V., additional, Alexandre, H., additional, Eric, R., additional, Cantaluppi, V., additional, Medica, D., additional, Quercia, A. D., additional, Figliolini, F., additional, Dellepiane, S., additional, Randone, O., additional, Segoloni, G. P., additional, Camussi, G., additional, Ahn, B.-H., additional, Kim, S. H., additional, Yasue Saito Miyagi, M., additional, Camara, N., additional, Cerqueira Leite Seelaender, M., additional, Maceratesi Enjiu, L., additional, Estler Rocha Guilherme, P., additional, Pisciottano, M., additional, Hiyane, M., additional, Yuri Hayashida, C., additional, De Andrade Oliveira, V., additional, Olsen Saraiva Camara, N., additional, Tami Amano, M., additional, Sancho-Martinez, S. M., additional, Sanchez-Juanes, F., additional, Vicente, L., additional, Gonzalez-Buitrago, J. M., additional, Morales, A. I., additional, Lopez-Novoa, J. M., additional, Lopez-Hernandez, F. J., additional, Chen, J.-S., additional, Chang, L.-C., additional, Chen, C.-C., additional, Park, M. Y., additional, Choi, S. J., additional, Kim, J. G., additional, Hwang, S. D., additional, Vicente-Vicente, L., additional, Ferreira, L., additional, Prieto, M., additional, Garcia-Sanchez, O., additional, Sevilla, M. A., additional, Lopez-Novoa, F. J., additional, Christoph, K., additional, Kuper, C., additional, Maria-Luisa, F., additional, Franz-Xaver, B., additional, Neuhofer, W., additional, Vervaet, B., additional, Le Clef, N., additional, Verhulst, A., additional, D'haese, P., additional, Tanaka, T., additional, Yamaguchi, J., additional, Eto, N., additional, Kojima, I., additional, Fujita, T., additional, Nangaku, M., additional, Wystrychowski, A., additional, Wystrychowski, G., additional, Obuchowicz, E., additional, Grzeszczak, W., additional, Wiecek, A., additional, Esposito, C., additional, Torreggiani, M., additional, Castoldi, F., additional, Migotto, C., additional, Serpieri, N., additional, Grosjean, F., additional, Manini, A., additional, Pertile, E., additional, and Dal Canton, A., additional

Published
2012
Full Text
View/download PDF

28. Transplantation: basic science and immune-tolerance

Author

Sugawara, M., primary, Ichimura, S., additional, Kokubo, K., additional, Shimbo, T., additional, Hirose, M., additional, Kobayashi, H., additional, Hribova, P., additional, Brabcova, I., additional, Honsova, E., additional, Viklicky, O., additional, Kute, V. B., additional, Shah, P. R., additional, Vanikar, A. V., additional, Gumber, M. R., additional, Patel, H. V., additional, Modi, P. R., additional, Trivedi, H. L., additional, Trivedi, V. B., additional, Nusrath, S., additional, Minz, M., additional, Walker Minz, R., additional, Sharma, A., additional, Singh, S., additional, Jha, V., additional, Joshi, K., additional, Richter, R., additional, Kohler, S., additional, Qidan, S., additional, Scheuermann, E., additional, Kachel, H.-G., additional, Gossmann, J., additional, Gauer, S., additional, Seifried, E., additional, Geiger, H., additional, Seidl, C., additional, Hauser, I. A., additional, Hanssen, L., additional, Frye, B., additional, Ostendorf, T., additional, Alidousty, C., additional, Djudjaj, S., additional, Boor, P., additional, Rauen, T., additional, Floege, J., additional, Mertens, P., additional, Raffetseder, U., additional, Garcia-Cenador, B., additional, Lopez-Novoa, J. M., additional, Iniguez, M., additional, Fernandez, V., additional, Perez de Obanos, P., additional, Ruiz, J., additional, Sanz-Gimenez, J. R., additional, Lopez-Marcos, J. F., additional, Garcia-Criado, J., additional, Van Craenenbroeck, A. H., additional, Anguille, S. H., additional, Jurgens, A., additional, Cools, N., additional, Van Camp, K., additional, Stein, B., additional, Nijs, G., additional, Berneman, Z., additional, Ieven, M., additional, Van Damme, P., additional, Van Tendeloo, V., additional, Verpooten, G. A., additional, Gohel, K., additional, Hegde, U., additional, Gang, S., additional, Rajapurkar, M., additional, Erdogmus, S., additional, Sengul, S., additional, Kocak, S., additional, Kurultak, I., additional, Kutlay, S., additional, Keven, K., additional, Erbay, B., additional, Erturk, S., additional, Kimura, S., additional, Imura, J., additional, Atsumi, H., additional, Fujimoto, K., additional, Chikazawa, Y., additional, Nakagawa, M., additional, Hayama, T., additional, Okuyama, H., additional, Yamaya, H., additional, Yokoyama, H., additional, Libetta, C., additional, Canevari, M., additional, Sepe, V., additional, Margiotta, E., additional, Meloni, F., additional, Martinelli, C., additional, Borettaz, I., additional, Esposito, P., additional, Portalupi, V., additional, Morosini, M., additional, Solari, N., additional, Dal Canton, A., additional, Rusai, K., additional, Schmaderer, C., additional, Hermans, R., additional, Lutz, J., additional, Heemann, U., additional, Baumann, M., additional, Cantaluppi, V., additional, Tamagnone, M., additional, Dellepiane, S., additional, Medica, D., additional, Dolla, C., additional, Messina, M., additional, Manzione, A. M., additional, Tognarelli, G., additional, Ranghino, A., additional, Biancone, L., additional, Camussi, G., additional, Segoloni, G. P., additional, Ozkurt, S., additional, Sahin, G., additional, Degirmenci, N., additional, Temiz, G., additional, Musmul, A., additional, Birdane, A., additional, Tek, M., additional, Tekin, N., additional, Akyuz, F., additional, Yalcin, A. U., additional, and Lopez-Valverde, A., additional

Published
2011
Full Text
View/download PDF

29. Experimental models

Author

Bussolati, B., primary, Moggio, A., additional, Collino, F., additional, Grange, C., additional, Camussi, G., additional, Cantaluppi, V., additional, Gatti, S., additional, Medica, D., additional, Figliolini, F., additional, Bruno, S., additional, Deregibus, M. C., additional, Sordi, A., additional, Biancone, L., additional, Tetta, C., additional, Segoloni, G. P., additional, Castellano, G., additional, Curci, C., additional, Stasi, A., additional, Cariello, M., additional, Loverre, A., additional, Simone, S., additional, Tataranni, T., additional, Ditonno, P., additional, Lucarelli, G., additional, Battaglia, M., additional, Crovace, A., additional, Staffieri, F., additional, Gesualdo, L., additional, Schena, F. P., additional, Grandaliano, G., additional, Kim, S., additional, Heo, N. J., additional, Lee, J. W., additional, Oh, Y. K., additional, Na, K. Y., additional, Joo, K. W., additional, Earm, J.-H., additional, Han, J. S., additional, Loureiro, J., additional, Aguilera, A., additional, Selgas, R., additional, Sandoval, P., additional, Albar-Vizcaino, P., additional, Perez-Lozano, M. L., additional, Ruiz-Carpio, V., additional, Borras-Cuesta, F., additional, Dotor, J., additional, Lopez-Cabrera, M., additional, Henley, C., additional, Davis, J., additional, Lee, P., additional, Wong, S., additional, Salyers, K., additional, Wagner, M., additional, Jung, J., additional, Nguyen, H., additional, van der Valk, M., additional, Jackson, J., additional, Serafino, R., additional, Jin, L., additional, Willcockson, M., additional, Ward, S., additional, Turk, J., additional, Lu, J. Y.- L., additional, Fu, A., additional, Richards, W., additional, Reagan, J. D., additional, Medina, J., additional, Li, A.-R., additional, and Liu, J., additional

Published
2011
Full Text
View/download PDF

33. Acute Tubular Injury is Associated With Severe Traumatic Brain Injury: in Vitro Study on Human Tubular Epithelial Cells

Author

Vito Marco Ranieri, Luciana Mascia, Vincenzo Cantaluppi, Barbara Assenzio, Vito Fanelli, Davide Medica, Ilaria Deambrosis, Fulvia Giaretta, Federica Civiletti, Anna Teresa Mazzeo, Civiletti F., Assenzio B., Mazzeo A.T., Medica D., Giaretta F., Deambrosis I., Fanelli V., Ranieri V.M., Cantaluppi V., and Mascia L.

Subjects
0301 basic medicine, Male, Pathology, lcsh:Medicine, Apoptosis, Lipocalin, Kidney Tubules, Proximal, chemistry.chemical_compound, 0302 clinical medicine, Brain Injuries, Traumatic, Medicine, Prospective Studies, lcsh:Science, Cells, Cultured, Kidney, Multidisciplinary, Acute kidney injury, Acute Kidney Injury, Middle Aged, Lipocalins, Low Density Lipoprotein Receptor-Related Protein-2, medicine.anatomical_structure, Cytokines, Female, Human, Adult, medicine.medical_specialty, Traumatic brain injury, Urinary system, Acute Kidney Injury, Lipocalins, Neutrophil gelatinase-associated, Article, 03 medical and health sciences, Young Adult, Lipocalin-2, Humans, Viability assay, Cytokine, Creatinine, Epithelial Cell, business.industry, lcsh:R, Neutrophil gelatinase-associated, Brain injuries, epithelial cells, Apoptosi, Epithelial Cells, Biomarker, medicine.disease, Acute Kidney Injury | Lipocalins | Neutrophil gelatinase-associated, Prospective Studie, 030104 developmental biology, chemistry, lcsh:Q, business, Biomarkers, 030217 neurology & neurosurgery
Abstract

Acute kidney injury following traumatic brain injury is associated with poor outcome. We investigated in vitro the effects of plasma of brain injured patients with acute tubular kidney injury on kidney tubular epithelial cell function. we performed a prospective observational clinical study in ICU in a trauma centre of the University hospital in Italy including twenty-three ICU patients with traumatic brain injury consecutively enrolled. Demographic data were recorded on admission: age 39 ± 19, Glasgow Coma Score 5 (3–8). Neutrophil Gelatinase-Associated Lipocalin and inflammatory mediators were measured in plasma on admission and after 24, 48 and 72 hours; urine were collected for immunoelectrophoresis having healthy volunteers as controls. Human renal proximal tubular epithelial cells were stimulated with patients or controls plasma. Adhesion of freshly isolated human neutrophils and trans-epithelial electrical resistance were assessed; cell viability (XTT assay), apoptosis (TUNEL staining), Neutrophil Gelatinase-Associated Lipocalin and Megalin expression (quantitative real-time PCR) were measured. All patients with normal serum creatinine showed increased plasmatic Neutrophil Gelatinase-Associated Lipocalin and increased urinary Retinol Binding Protein and α1-microglobulin. Neutrophil Gelatinase-Associated Lipocalin was significantly correlated with both inflammatory mediators and markers of tubular damage. Patient’ plasma incubated with tubular cells significantly increased adhesion of neutrophils, reduced trans-epithelial electrical resistance, exerted a cytotoxic effect and triggered apoptosis and down-regulated the endocytic receptor Megalin compared to control. Plasma of brain injured patients with increased markers of subclinical acute kidney induced a pro-inflammatory phenotype, cellular dysfunction and apoptotic death in tubular epithelial cells.

Published
2019

34. Individualized homeopathic medicines in preventing the progression from pre-diabetes to diabetes: A double-blind, randomized, placebo-controlled, parallel-arm trial.

Author

Banerjee A, Ganguly S, Saha S, Bhattacharyya P, Naskar S, Mukherjee D, Ghosh S, Maji P, Saha S, Shaikh AR, Ghosh P, Chatterjee C, Koley M, and Mukherjee SK

Subjects
Humans, Double-Blind Method, Male, Female, Middle Aged, Adult, India, Homeopathy methods, Yoga, Glucose Tolerance Test, Diabetes Mellitus, Type 2 drug therapy, Treatment Outcome, Prediabetic State drug therapy, Blood Glucose drug effects, Blood Glucose metabolism, Glycated Hemoglobin metabolism, Disease Progression, Materia Medica therapeutic use
Abstract

Context: Pre-diabetes is a significant public health problem worldwide. India has a very high rate of progression from pre-diabetes to diabetes, 75-78 per thousand persons per year., Objective: To study the efficacy of individualized homeopathic medicinal products (HMPs) against placebos in preventing the progression from pre-diabetes to diabetes., Design: Six-month, double-blind, randomized (1:1), two parallel arms, placebo-controlled trial., Setting: Outpatient departments of D. N. De Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India., Patients: Sixty participants with pre-diabetes., Interventions: Verum: HMPs plus yoga therapy (YT; n = 30); control: identical-looking placebos plus YT (n = 30)., Main Outcome Measures: The primary efficacy endpoint was the proportion of participants progressing from pre-diabetes to diabetes, measured after three and six months. Secondary outcomes comprised of fasting blood glucose (FBS), oral glucose tolerance test (OGTT), glycated hemoglobin percentage (HbA1c%), lipid profile, liver enzymes (alanine transaminase, aspartate transaminase), urea and creatinine, and Measure Yourself Medical Outcome Profile version 2 (MYMOP-2); all measured after 3 and 6 months., Results: The proportion of participants converted from pre-diabetics to diabetics (n/N; n = diabetics, N = prediabetics) was significantly less in the verum group than control: HbA1C% (month 3: verum - 2/30 versus control - 11/30, p = 0.003; month 6: 3/30 vs. 2/30, p = 0.008), OGTT (month 3: 0/30 vs. 8/30, p = 0.015; month 6: 0/30 vs. 1/30, p = 0.008), but not according to FBS (month 3: 1/30 vs. 1/30, p = 0.779; month 6: 1/30 vs. 3/30, p = 0.469). Several secondary outcomes also revealed significant improvements in the verum group than in placebo: HbA1C% (p < 0.001), OGTT (p = 0.001), serum ALT (p = 0.031), creatinine (p = 0.012), and MYMOP-2 profile scores (p < 0.001). Sulphur, Bryonia alba, and Thuja occidentalis were the most frequently indicated medicines. Thus, HMPs outperformed placebos by successfully preventing the progression of pre-diabetes to diabetes., Trial Registration: Clinical Trials Registry - India CTRI/2022/04/042,026; UTN: U1111-1277-0021., (Copyright © 2024 Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

35. High-volume hemofiltration does not protect human kidney endothelial and tubular epithelial cells from septic plasma-induced injury.

Author

Medica D, Quercia AD, Marengo M, Fanelli V, Castellano G, Fabbrini P, Migliori M, Merlotti G, Camussi G, Joannes-Boyau O, Honorè PM, and Cantaluppi V

Subjects
Humans, Male, Acute Kidney Injury therapy, Acute Kidney Injury etiology, Female, Middle Aged, Apoptosis, Aged, Kidney Tubules metabolism, Cytokines metabolism, Cytokines blood, Cell Adhesion, Sepsis therapy, Endothelial Cells metabolism, Hemofiltration methods, Epithelial Cells metabolism
Abstract

High volume hemofiltration (HVHF) could remove from plasma inflammatory mediators involved in sepsis-associated acute kidney injury (SA-AKI). The IVOIRE trial did not show improvements of outcome and organ dysfunction using HVHF. The aim of this study was to evaluate in vitro the biological effects of plasma of patients treated by HVHF or standard volume hemofiltration (SVHF). We evaluated leukocyte adhesion, apoptosis and functional alterations of endothelial cells (EC) and tubular epithelial cells (TEC). In vitro data were correlated with plasma levels of TNF-α, Fas-Ligand (FasL), CD40-Ligand (CD40L), von Willebrand Factor (vWF) and endothelial-derived microparticles. An experimental model of in vitro hemofiltration using LPS-activated blood was established to assess cytokine mass adsorption during HVHF or SVHF. Plasma concentrations of TNF-ɑ, FasL, CD40L and von Willebrand Factor (vWF) were elevated at the start (d1h0) of both HVHF and SVHF, significantly decreased after 6 h (d1h6), remained stable after 12 h (d1h12) and then newly increased at 48 h (d3h0). Plasma levels of all these molecules were similar between HVHF- and SVHF-treated patients at all time points considered. In addition, the levels of endothelial microparticles remained always elevated, suggesting the presence of a persistent microvascular injury. Plasma from septic patients induced leukocyte adhesion on EC and TEC through up-regulation of adhesion receptors. Moreover, on EC, septic plasma induced a cytotoxic and anti-angiogenic effect. On TEC, septic plasma exerted a direct pro-apoptotic effect via Fas up-regulation and caspase activation, loss of polarity, altered expression of megalin and tight junction molecules with an impaired ability to internalize albumin. The inhibition of plasma-induced cell injury was concomitant to the decrease of TNF-α, Fas-Ligand and CD40-Ligand levels. The protective effect of both HVHF and SVHF was time-limited, since a further increase of circulating mediators and plasma-induced cell injury was observed after 48 h (d3h0). No significant difference of EC/TEC damage were observed using HVHF- or SVHF-treated plasma. The in vitro hemofiltration model confirmed the absence of a significant modulation of cytokine adsorption between HVHF and SVHF. In comparison to SVHF, HVHF did not increase inflammatory cytokine clearance and did not reverse the detrimental effects of septic plasma-induced EC and TEC injury. Further studies using adsorptive membranes are needed to evaluate the potential role of high dose convective therapies in the limitation of the harmful activity of plasma soluble factors involved in SA-AKI.Trial registration IVOIRE randomized clinical trial; ClinicalTrials.gov (NCT00241228) (18/10/2005)., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

36. Individualized Homeopathic Medicines in the Treatment of Knee Osteoarthritis: Double-Blind, Randomized, Placebo-Controlled Feasibility Trial.

Author

Bhattacharyya S, Chatterjee C, Saha S, Naskar S, Bhattacharya P, Alam SM, Sengupta S, Ahamed S, Shaikh AR, Koley M, Ghosh P, and Mukherjee SK

Subjects
Humans, Double-Blind Method, Male, Female, Middle Aged, Materia Medica therapeutic use, Treatment Outcome, India, Aged, Quality of Life, Precision Medicine methods, Adult, Pain Measurement methods, Osteoarthritis, Knee drug therapy, Feasibility Studies, Homeopathy methods
Abstract

Introduction:  This study aimed at examining the feasibility issues of comparing individualized homeopathic medicines (IHMs) with identical-looking placebos for treating knee osteoarthritis (OA)., Methods:  Forty eligible patients participated in this double-blind, randomized (1:1), placebo-controlled feasibility trial in the outpatient clinics of a homeopathic hospital in West Bengal, India. Either IHMs or identical-looking placebos were administered, along with mutually agreed-upon concomitant care guidelines. The Knee Injury and Osteoarthritis Outcome Score (KOOS) was the primary outcome measure, along with derived Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores from KOOS. The EQ-5D-5L questionnaire and Visual Analog Scale (VAS) were the secondary outcomes. All were measured at baseline and after 2 months. Group differences and effect sizes (Cohen's d ) were estimated using an intention-to-treat approach. p -Values less than 0.05 (two-tailed) were considered statistically significant., Results:  Enrolment/screening and trial retention rates were 43% and 85% respectively. Recruitment was difficult owing to the coronavirus disease 2019 (COVID-19) lockdown. Group differences were statistically significant, favoring IHMs against placebos in all the KOOS sub-scales: symptoms ( p  < 0.001), pain ( p  = 0.002), activities of daily living ( p  < 0.001), sports or recreation ( p  = 0.016), and quality of life ( p  = 0.002). Derived WOMAC scores from KOOS favored IHMs against placebos: stiffness ( p  < 0.001) and pain ( p  < 0.001). The EQ-5D-5L questionnaire score ( p  < 0.001) and EQ-5D-5L VAS scores ( p  < 0.001) also yielded significant results, favoring IHMs over placebos. All the effect sizes ranged from moderate to large. Sulphur was the most frequently prescribed homeopathic medication. Neither group reported any harm or serious adverse events., Conclusion:  Although recruitment was sub-optimal due to prevailing COVID-19 conditions during the trial, the action of IHMs was found to be superior to that of placebos in the treatment of knee OA. Larger and more definitive studies, with independent replications, are warranted in order to substantiate the findings., Trial Registration:  CTRI/2021/02/031453., Competing Interests: None declared., (Faculty of Homeopathy. This article is published by Thieme.)

Published
2024
Full Text
View/download PDF

37. Treatment of Menstrual Irregularities with Individualized Homeopathic Medicinal Products in Early Reproductive Females: A Double-Blind, Randomized, Placebo-Controlled Trial.

Author

Nag U, Pal RK, Saha S, Alam SM, Parvin T, Gole R, Debnath P, Sengupta S, Koley M, Roy U, Akram J, Shaikh AR, Koley M, and Mukherjee SK

Abstract

Objectives: Prevalence of irregular menstrual cycle ranges from 81.7% to 96.3%. Recent research suggested that homeopathy is one of the most popular choices for women with various gynecological disorders. This trial was aimed at differentiating individualized homeopathic medicinal products (IHMPs) from identical-looking placebos in the treatment of menstrual irregularities in early reproductive women. Design: Double-blind, randomized (1:1), two parallel arms, placebo-controlled trial. Setting: D. N. De Homoeopathic Medical College & Hospital, Kolkata, West Bengal, India. Subjects: Ninety-two females with menstrual irregularities. Interventions: Group verum ( n = 46; IHMPs plus concomitant care) versus group control ( n = 46; placebos plus concomitant care). Outcome Measures: Primary-The proportion of early reproductive females in whom menstrual irregularities can be corrected for consecutive three cycles; Secondary-Menstrual Distress Questionnaire (MDQ) total score; all of them were measured at baseline and every month, up to 4 months. Results: Intention-to-treat sample ( n = 92) was analyzed. Group differences were examined by chi-squared tests with categorical outcomes, two-way repeated measure analysis of variance accounting for the time-effect interactions, and unpaired t -tests comparing the mean estimates obtained individually every month. The level of significance was set at p < 0.05 two-tailed. After 4 months of intervention, the group difference in the primary outcome was nonsignificant statistically-IHMPs: 22/46 v/s placebo: 24/46, chi-square (Yates corrected) = 0.043, p = 0.835. The improvement observed in the MDQ total score ( F 1 , 90 = 0.054, p = 0.816) and subscales scores were higher in the IHMPs group than in placebos, however statistically nonsignificant in most of the occasions, except for the behavioral change subscale ( F 1 , 90 = 0.029, p < 0.001). Pulsatilla nigricans was the most frequently prescribed medicine. Kent's Repertory and Zandvoort's Complete Repertory were the most frequently used repertories. No harm or serious adverse events were reported from either group. Conclusions: The analysis failed to demonstrate clearly that IHMPs were effective beyond placebos in all but one of the outcomes. More appropriate outcome measures may be sought for future trials. Clinical Trial Registration Number: CTRI/2022/04/041659.

Published
2024
Full Text
View/download PDF

38. Estimation of the Likelihood Ratio of Different Symptoms for Six Homeopathic Medicines: Prognostic Factor Research.

Author

Mohanta A, Sardar N, Chakraborty K, Sarkar M, Saha T, Deb A, Hossain MS, Basu A, Samim S, Bhattacharyya S, Saha S, Basu B, Sen A, Giri M, Debnath P, Saha S, Koley M, Mukherjee SK, and Rutten L

Abstract

Background:   Arsenicum album , Causticum , Nux vomica , Pulsatilla nigricans , Rhus toxicodendron and Sulphur are frequently prescribed homeopathic medicines; however, their symptoms, as mentioned in different homeopathic literature works, have rarely been investigated systematically. Likelihood ratio (LR), based on Bayesian statistics, may reflect a better estimation of the strengths of symptoms than the existing entries in the homeopathic literature., Methods:  A prospective, longitudinal, analytical patient outcome study was conducted in the outpatient departments of D. N. De Homeopathic Medical College and Hospital, Kolkata, on 1,954 patients over 21 months. The outcomes were recorded at each follow-up using the Outcome Related to Impact on Daily Living (ORIDL) +4 to -4 scale. The average period of treatment for each participant was 3 months. The LRs of four symptoms for each of the six selected medicines were calculated., Results:  One hundred and two different remedies were prescribed. The prevalence, LR + , and LR - , with respective 95% confidence intervals, of different symptoms were reported. The study found that the following symptoms had particularly high LR+ scores: "intense sympathy for the suffering of others" ( Causticum , LR+ = 12.0); "dyspepsia from business anxiety" ( Nux vomica , LR+ = 27.4); "burning pain relieved by heat" ( Arsenicum album , LR+ = 29.6); "envy" ( Pulsatilla nigricans , LR+ = 13.2); "desire for milk" ( Rhus toxicodendron , LR+ = 7.5); "very selfish, no regard for others" ( Sulphur , LR+ = 20.6). The findings corroborated well with the presentation of the symptoms in different homeopathic materia medica and repertories. ORIDL scores of +2 or greater were identified most prominently for Pulsatilla nigricans ( n  = 138) and Sulphur ( n  = 119)., Conclusion:  There was adequate evidence to attribute all the assessed symptoms to the medicines investigated. Further studies with a larger population are warranted to tackle the possible confirmation bias., Competing Interests: None declared., (Faculty of Homeopathy. This article is published by Thieme.)

Published
2024
Full Text
View/download PDF

39. Finding the Needle in the Haystack: Serological and Urinary Biomarkers in Behçet's Disease: A Systematic Review.

Author

Arbrile M, Radin M, Medica D, Miraglia P, Rilat L, Cecchi I, Foddai SG, Barinotti A, Menegatti E, Roccatello D, and Sciascia S

Subjects
Humans, Retrospective Studies, Prospective Studies, Case-Control Studies, Biomarkers, Behcet Syndrome diagnosis
Abstract

Urinary and serological markers play an essential role in the diagnostic process of autoimmune diseases. However, to date, specific and reliable biomarkers for diagnosing Behçet's disease (BD) are still lacking, negatively affecting the management of these patients. To analyze the currently available literature on serological and urinary BD biomarkers investigated in the last 25 years, we performed a systematic literature review using the Population, Intervention, Comparison, and Outcomes (PICO) strategy. One hundred eleven studies met the eligibility criteria (6301 BD patients, 5163 controls). Most of them were retrospective, while five (5%) were prospective. One hundred ten studies (99%) investigated serological biomarkers and only two (2%) focused on urinary biomarkers. One hundred three studies (93%) explored the diagnostic potential of the biomolecules, whereas sixty-two (56%) tested their effect on disease activity monitoring. Most articles reported an increase in inflammatory markers and pro-oxidant molecules, with a decrease in antioxidants. Promising results have been shown by the omics sciences, offering a more holistic approach. Despite the vast number of investigated markers, existing evidence indicates a persistent gap in BD diagnostic/prognostic indices. While new steps have been taken in the direction of pathogenesis and disease monitoring, international efforts for the search of a diagnostic marker for BD are still needed.

Published
2023
Full Text
View/download PDF

41. Extracellular Vesicles Derived from Endothelial Progenitor Cells Protect Human Glomerular Endothelial Cells and Podocytes from Complement- and Cytokine-Mediated Injury.

Author

Medica D, Franzin R, Stasi A, Castellano G, Migliori M, Panichi V, Figliolini F, Gesualdo L, Camussi G, and Cantaluppi V

Subjects
Apoptosis drug effects, Apoptosis genetics, Cell Movement drug effects, Cell Proliferation drug effects, Coculture Techniques, Endothelial Progenitor Cells cytology, Endothelial Progenitor Cells metabolism, Extracellular Vesicles chemistry, Gene Expression Regulation, Hepatocyte Growth Factor genetics, Hepatocyte Growth Factor metabolism, Humans, Intercellular Adhesion Molecule-1 genetics, Intercellular Adhesion Molecule-1 metabolism, L-Selectin genetics, L-Selectin metabolism, MicroRNAs genetics, MicroRNAs metabolism, Neovascularization, Physiologic drug effects, Neovascularization, Physiologic genetics, Paracrine Communication drug effects, Podocytes cytology, Podocytes metabolism, Primary Cell Culture, Reactive Oxygen Species antagonists & inhibitors, Reactive Oxygen Species metabolism, Vascular Cell Adhesion Molecule-1 genetics, Vascular Cell Adhesion Molecule-1 metabolism, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A metabolism, Complement C5a pharmacology, Endothelial Progenitor Cells drug effects, Extracellular Vesicles metabolism, Interleukin-6 pharmacology, Podocytes drug effects, Tumor Necrosis Factor-alpha pharmacology
Abstract

Glomerulonephritis are renal inflammatory processes characterized by increased permeability of the Glomerular Filtration Barrier (GFB) with consequent hematuria and proteinuria. Glomerular endothelial cells (GEC) and podocytes are part of the GFB and contribute to the maintenance of its structural and functional integrity through the release of paracrine mediators. Activation of the complement cascade and pro-inflammatory cytokines (CK) such as Tumor Necrosis Factor α (TNF-α) and Interleukin-6 (IL-6) can alter GFB function, causing acute glomerular injury and progression toward chronic kidney disease. Endothelial Progenitor Cells (EPC) are bone-marrow-derived hematopoietic stem cells circulating in peripheral blood and able to induce angiogenesis and to repair injured endothelium by releasing paracrine mediators including Extracellular Vesicles (EVs), microparticles involved in intercellular communication by transferring proteins, lipids, and genetic material (mRNA, microRNA, lncRNA) to target cells. We have previously demonstrated that EPC-derived EVs activate an angiogenic program in quiescent endothelial cells and renoprotection in different experimental models. The aim of the present study was to evaluate in vitro the protective effect of EPC-derived EVs on GECs and podocytes cultured in detrimental conditions with CKs (TNF-α/IL-6) and the complement protein C5a. EVs were internalized in both GECs and podocytes mainly through a L-selectin-based mechanism. In GECs, EVs enhanced the formation of capillary-like structures and cell migration by modulating gene expression and inducing the release of growth factors such as VEGF-A and HGF. In the presence of CKs, and C5a, EPC-derived EVs protected GECs from apoptosis by decreasing oxidative stress and prevented leukocyte adhesion by inhibiting the expression of adhesion molecules (ICAM-1, VCAM-1, E-selectin). On podocytes, EVs inhibited apoptosis and prevented nephrin shedding induced by CKs and C5a. In a co-culture model of GECs/podocytes that mimicked GFB, EPC-derived EVs protected cell function and permeselectivity from inflammatory-mediated damage. Moreover, RNase pre-treatment of EVs abrogated their protective effects, suggesting the crucial role of RNA transfer from EVs to damaged glomerular cells. In conclusion, EPC-derived EVs preserved GFB integrity from complement- and cytokine-induced damage, suggesting their potential role as therapeutic agents for drug-resistant glomerulonephritis.

Published
2021
Full Text
View/download PDF

42. PMMA-Based Continuous Hemofiltration Modulated Complement Activation and Renal Dysfunction in LPS-Induced Acute Kidney Injury.

Author

Stasi A, Franzin R, Divella C, Sallustio F, Curci C, Picerno A, Pontrelli P, Staffieri F, Lacitignola L, Crovace A, Cantaluppi V, Medica D, Ronco C, de Cal M, Lorenzin A, Zanella M, Pertosa GB, Stallone G, Gesualdo L, and Castellano G

Subjects
Acute Kidney Injury diagnosis, Acute Kidney Injury mortality, Animals, Biomarkers, C-Reactive Protein genetics, C-Reactive Protein metabolism, Disease Models, Animal, Fibrosis, Gene Expression, Humans, Immunohistochemistry, Inflammation Mediators, Kidney Function Tests, Renal Dialysis, Sepsis complications, Serum Amyloid P-Component genetics, Serum Amyloid P-Component metabolism, Swine, Treatment Outcome, Acute Kidney Injury etiology, Acute Kidney Injury therapy, Complement Activation drug effects, Hemofiltration adverse effects, Hemofiltration methods, Lipopolysaccharides adverse effects, Polymethyl Methacrylate administration & dosage
Abstract

Sepsis-induced acute kidney injury (AKI) is a frequent complication in critically ill patients, refractory to conventional treatments. Aberrant activation of innate immune system may affect organ damage with poor prognosis for septic patients. Here, we investigated the efficacy of polymethyl methacrylate membrane (PMMA)-based continuous hemofiltration (CVVH) in modulating systemic and tissue immune activation in a swine model of LPS-induced AKI. After 3 h from LPS infusion, animals underwent to PMMA-CVVH or polysulfone (PS)-CVVH. Renal deposition of terminal complement mediator C5b-9 and of Pentraxin-3 (PTX3) deposits were evaluated on biopsies whereas systemic Complement activation was assessed by ELISA assay. Gene expression profile was performed from isolated peripheral blood mononuclear cells (PBMC) by microarrays and the results validated by Real-time PCR. Endotoxemic pigs presented oliguric AKI with increased tubulo-interstitial infiltrate, extensive collagen deposition, and glomerular thrombi; local PTX-3 and C5b-9 renal deposits and increased serum activation of classical and alternative Complement pathways were found in endotoxemic animals. PMMA-CVVH treatment significantly reduced tissue and systemic Complement activation limiting renal damage and fibrosis. By microarray analysis, we identified 711 and 913 differentially expressed genes with a fold change >2 and a false discovery rate <0.05 in endotoxemic pigs and PMMA-CVVH treated-animals, respectively. The most modulated genes were Granzyme B, Complement Factor B, Complement Component 4 Binding Protein Alpha, IL-12, and SERPINB-1 that were closely related to sepsis-induced immunological process. Our data suggest that PMMA-based CVVH can efficiently modulate immunological dysfunction in LPS-induced AKI., Competing Interests: GC reports research grant donation from TORAY (Toray Industries, Inc), during the conduct of the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Stasi, Franzin, Divella, Sallustio, Curci, Picerno, Pontrelli, Staffieri, Lacitignola, Crovace, Cantaluppi, Medica, Ronco, de Cal, Lorenzin, Zanella, Pertosa, Stallone, Gesualdo and Castellano.)

Published
2021
Full Text
View/download PDF

43. Targeted and untargeted quantification of quorum sensing signalling molecules in bacterial cultures and biological samples via HPLC-TQ MS techniques.

Author

Dal Bello F, Zorzi M, Aigotti R, Medica D, Fanelli V, Cantaluppi V, Amante E, Orlandi VT, and Medana C

Subjects
Acyl-Butyrolactones chemistry, Humans, Limit of Detection, Molecular Structure, Multiple Organ Failure blood, Multiple Organ Failure etiology, Quinolones chemistry, Reproducibility of Results, Sepsis blood, Sepsis complications, Sepsis microbiology, Virulence Factors blood, Acyl-Butyrolactones analysis, Chromatography, High Pressure Liquid methods, Mass Spectrometry methods, Pseudomonas aeruginosa metabolism, Quinolones analysis, Quorum Sensing, Signal Transduction
Abstract

Quorum sensing (QS) is the ability of some bacteria to detect and to respond to population density through signalling molecules. QS molecules are involved in motility and cell aggregation mechanisms in diseases such as sepsis. Few biomarkers are currently available to diagnose sepsis, especially in high-risk conditions. The aim of this study was the development of new analytical methods based on liquid chromatography-mass spectrometry for the detection and quantification of QS signalling molecules, including N-acyl homoserine lactones (AHL) and hydroxyquinolones (HQ), in biofluids. Biological samples used in the study were Pseudomonas aeruginosa bacterial cultures and plasma from patients with sepsis. We developed two MS analytical methods, based on neutral loss (NL) and product ion (PI) experiments, to identify and characterize unknown AHL and HQ molecules. We then established a multiple-reaction-monitoring (MRM) method to quantify specific QS compounds. We validated the HPLC-MS-based approaches (MRM-NL-PI), and data were in accord with the validation guidelines. With the NL and PI MS-based methods, we identified and characterized 3 and 13 unknown AHL and HQ compounds, respectively, in biological samples. One of the newly found AHL molecules was C12-AHL, first quantified in Pseudomonas aeruginosa bacterial cultures. The MRM quantitation of analytes in plasma from patients with sepsis confirmed the analytical ability of MRM for the quantification of virulence factors during sepsis. Graphical abstract.

Published
2021
Full Text
View/download PDF

44. Mercurius solubilis as Genus Epidemicus for the COVID-19 Pandemic.

Author

Vaishampayan S, Mutreja K, Lambe S, Shah J, and Shaikh G

Subjects
Humans, India, Mercury Compounds administration & dosage, SARS-CoV-2, Treatment Outcome, Homeopathy, Mercury Compounds therapeutic use, Pandemics, Pneumonia, Viral drug therapy, COVID-19 Drug Treatment
Abstract

Competing Interests: None declared.

Published
2020
Full Text
View/download PDF

45. Regenerative Role of Stem Cell-Derived Extracellular Vesicles in Acute Kidney Injury.

Author

Medica D, Dellepiane S, and Cantaluppi V

Subjects
Humans, Kidney Glomerulus pathology, Acute Kidney Injury pathology, Extracellular Vesicles pathology, Regenerative Medicine, Stem Cells cytology
Abstract

Acute kidney injury (AKI) is a frequent complication of hospital admission and worsens short- and long-term patients' prognosis. Currently, AKI treatment remains supportive and no therapy has proven significant benefit in clinical trials. Stem cells (SCs) are a promising therapeutic option, but their translation to the clinical setting is limited by the risk of rejection or aberrant differentiation. Numerous studies have shown how SC effects are mediated by paracrine factors such as extracellular vesicles (EVs). In this review, we describe the preclinical evidence about EV efficacy in acute tubular and glomerular injury and the recently generated clinical data., (© 2020 S. Karger AG, Basel.)

Published
2020
Full Text
View/download PDF

46. Citrate anion improves chronic dialysis efficacy, reduces systemic inflammation and prevents Chemerin-mediated microvascular injury.

Author

Dellepiane S, Medica D, Guarena C, Musso T, Quercia AD, Leonardi G, Marengo M, Migliori M, Panichi V, Biancone L, Pizzarelli F, Camussi G, and Cantaluppi V

Subjects
C-Reactive Protein analysis, Chemokines blood, Endothelium, Vascular injuries, Endothelium, Vascular metabolism, Female, Fibrinogen analysis, Hemodialysis Solutions, Humans, Inflammation etiology, Interleukin-6 blood, Male, Microvessels metabolism, Middle Aged, Muscle, Smooth, Vascular injuries, Muscle, Smooth, Vascular metabolism, Renal Dialysis methods, Treatment Outcome, Chemokines metabolism, Citric Acid therapeutic use, Inflammation prevention & control, Microvessels injuries, Renal Dialysis adverse effects
Abstract

Systemic inflammation and uremic toxins (UT) determine the increased cardiovascular mortality observed in chronic hemodialysis (HD) patients. Among UT, the adipokine Chemerin induces vascular dysfunction by targeting both endothelial and vascular smooth muscular cells (EC and VSMC). As Citrate anion modulates oxidative metabolism, systemic inflammation and vascular function, we evaluated whether citrate-buffered dialysis improves HD efficiency, inflammatory parameters and chemerin-mediated microvascular injury. 45 patients were treated in sequence with acetate, citrate and, again, acetate-buffered dialysis solution (3 months per interval). At study admission and after each treatment switch, we evaluated dialysis efficacy and circulating levels of chemerin and different inflammatory biomarkers. In vitro, we stimulated EC and VSMC with patients' plasma and we investigated the role of chemerin as UT. Citrate dialysis increased HD efficacy and reduced plasma levels of CRP, fibrinogen, IL6 and chemerin. In vitro, patients' plasma induced EC and VSMC dysfunction. These effects were reduced by citrate-buffered solutions and paralleled by the decrease of chemerin levels. Consistently, chemerin receptor knockdown reduced EC and VSMC dysfunction. In conclusion, Switching from acetate to citrate improved dialysis efficacy and inflammatory parameters; in vitro, chemerin-induced EC and VSMC injury were decreased by using citrate as dialysis buffer.

Published
2019
Full Text
View/download PDF

47. Online Hemodiafiltration Inhibits Inflammation-Related Endothelial Dysfunction and Vascular Calcification of Uremic Patients Modulating miR-223 Expression in Plasma Extracellular Vesicles.

Author

Cavallari C, Dellepiane S, Fonsato V, Medica D, Marengo M, Migliori M, Quercia AD, Pitino A, Formica M, Panichi V, Maffei S, Biancone L, Gatti E, Tetta C, Camussi G, and Cantaluppi V

Subjects
Adult, Aged, Endothelium, Vascular metabolism, Endothelium, Vascular pathology, Female, Human Umbilical Vein Endothelial Cells, Humans, Inflammation blood, Inflammation immunology, Inflammation pathology, Inflammation therapy, Male, Middle Aged, Endothelium, Vascular immunology, Extracellular Vesicles immunology, Extracellular Vesicles metabolism, Gene Expression Regulation immunology, Hemodiafiltration, MicroRNAs blood, MicroRNAs immunology, Renal Insufficiency, Chronic blood, Renal Insufficiency, Chronic immunology, Renal Insufficiency, Chronic pathology, Renal Insufficiency, Chronic therapy, Uremia blood, Uremia immunology, Uremia pathology, Uremia therapy, Vascular Calcification blood, Vascular Calcification immunology, Vascular Calcification pathology, Vascular Calcification therapy
Abstract

Decreased inflammation and cardiovascular mortality are evident in patients with end-stage chronic kidney disease treated by online hemodiafiltration. Extracellular vesicles (EV) are mediators of cell-to-cell communication and contain different RNA types. This study investigated whether mixed online hemodiafiltration (mOL-HDF) beneficial effects associate with changes in the RNA content of plasma EV in chronic kidney disease patients. Thirty bicarbonate hemodialysis (BHD) patients were randomized 1:1 to continue BHD or switch to mOL-HDF. Concentration, size, and microRNA content of plasma EV were evaluated for 9 mo; we then studied EV effects on inflammation, angiogenesis, and apoptosis of endothelial cells (HUVEC) and on osteoblast mineralization of vascular smooth muscle cells (VSMC). mOL-HDF treatment reduced different inflammatory markers, including circulating CRP, IL-6, and NGAL. All hemodialysis patients showed higher plasma levels of endothelial-derived EV than healthy subjects, with no significant differences between BHD and mOL-HDF. However, BHD-derived EV had an increased expression of the proatherogenic miR-223 with respect to healthy subjects or mOL-HDF. Compared with EV from healthy subjects, those from hemodialysis patients reduced angiogenesis and increased HUVEC apoptosis and VSMC calcification; however, all these detrimental effects were reduced with mOL-HDF with respect to BHD. Cell transfection with miR-223 mimic or antagomiR proved the role of this microRNA in EV-induced HUVEC and VSMC dysfunction. The switch from BHD to mOL-HDF significantly reduced systemic inflammation and miR-223 expression in plasma EV, thus improving HUVEC angiogenesis and reducing VSMC calcification., (Copyright © 2019 by The American Association of Immunologists, Inc.)

Published
2019
Full Text
View/download PDF

48. Acute Tubular Injury is Associated With Severe Traumatic Brain Injury: in Vitro Study on Human Tubular Epithelial Cells.

Author

Civiletti F, Assenzio B, Mazzeo AT, Medica D, Giaretta F, Deambrosis I, Fanelli V, Ranieri VM, Cantaluppi V, and Mascia L

Subjects
Adult, Apoptosis, Biomarkers blood, Cells, Cultured, Cytokines blood, Female, Humans, Kidney Tubules, Proximal pathology, Lipocalin-2 blood, Low Density Lipoprotein Receptor-Related Protein-2 blood, Male, Middle Aged, Prospective Studies, Young Adult, Acute Kidney Injury etiology, Brain Injuries, Traumatic complications, Epithelial Cells pathology, Kidney Tubules, Proximal cytology
Abstract

Acute kidney injury following traumatic brain injury is associated with poor outcome. We investigated in vitro the effects of plasma of brain injured patients with acute tubular kidney injury on kidney tubular epithelial cell function. we performed a prospective observational clinical study in ICU in a trauma centre of the University hospital in Italy including twenty-three ICU patients with traumatic brain injury consecutively enrolled. Demographic data were recorded on admission: age 39 ± 19, Glasgow Coma Score 5 (3-8). Neutrophil Gelatinase-Associated Lipocalin and inflammatory mediators were measured in plasma on admission and after 24, 48 and 72 hours; urine were collected for immunoelectrophoresis having healthy volunteers as controls. Human renal proximal tubular epithelial cells were stimulated with patients or controls plasma. Adhesion of freshly isolated human neutrophils and trans-epithelial electrical resistance were assessed; cell viability (XTT assay), apoptosis (TUNEL staining), Neutrophil Gelatinase-Associated Lipocalin and Megalin expression (quantitative real-time PCR) were measured. All patients with normal serum creatinine showed increased plasmatic Neutrophil Gelatinase-Associated Lipocalin and increased urinary Retinol Binding Protein and α1-microglobulin. Neutrophil Gelatinase-Associated Lipocalin was significantly correlated with both inflammatory mediators and markers of tubular damage. Patient' plasma incubated with tubular cells significantly increased adhesion of neutrophils, reduced trans-epithelial electrical resistance, exerted a cytotoxic effect and triggered apoptosis and down-regulated the endocytic receptor Megalin compared to control. Plasma of brain injured patients with increased markers of subclinical acute kidney induced a pro-inflammatory phenotype, cellular dysfunction and apoptotic death in tubular epithelial cells.

Published
2019
Full Text
View/download PDF

49. Perfluorocarbon solutions limit tubular epithelial cell injury and promote CD133+ kidney progenitor differentiation: potential use in renal assist devices for sepsis-associated acute kidney injury and multiple organ failure.

Author

Cantaluppi V, Medica D, Quercia AD, Dellepiane S, Figliolini F, Virzì GM, Brocca A, Quaglia M, Marengo M, Olivieri C, Senzolo M, Garzotto F, Della Corte F, Castellano G, Gesualdo L, Camussi G, and Ronco C

Subjects
Acute Kidney Injury diagnosis, Acute Kidney Injury etiology, Aged, Aged, 80 and over, Animals, Cell Differentiation drug effects, Cell Proliferation drug effects, Cells, Cultured, Female, Humans, Kidney Tubules drug effects, Kidney Tubules metabolism, Kidney Tubules pathology, Male, Middle Aged, Multiple Organ Failure diagnosis, Multiple Organ Failure etiology, Sepsis pathology, Sepsis therapy, Stem Cells drug effects, Stem Cells metabolism, AC133 Antigen metabolism, Acute Kidney Injury therapy, Apoptosis drug effects, Fluorocarbons pharmacology, Multiple Organ Failure therapy, Sepsis complications, Stem Cells pathology
Abstract

Background: The renal assist device (RAD) is a blood purification system containing viable renal tubular epithelial cells (TECs) that has been proposed for the treatment of acute kidney injury (AKI) and multiple organ failure. Perfluorocarbons (PFCs) are oxygen carriers used for organ preservation in transplantation. The aim of this study was to investigate the effect of PFCs on hypoxia- and sepsis-induced TEC injury and on renal CD133+ progenitor differentiation in a microenvironment similar to the RAD., Methods: TECs were seeded in a polysulphone hollow fibre under hypoxia or cultured with plasma from 10 patients with sepsis-associated AKI in the presence or absence of PFCs and were tested for cytotoxicity (XTT assay), apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling assay, caspases, enzyme-linked immunosorbent assay, Fas/Fas Ligand pathway activation), mitochondrial activity, cell polarity [transepithelial electrical resistance (TEER)] and adenosine triphosphate production. The effect of PFCs on proliferation and differentiation of human CD133+ progenitors was also studied., Results: In the presence of PFCs, TECs seeded into the polysulphone hollow fibre showed increased viability and expression of insulin-like growth factor 1, hepatocyte growth factor and macrophage-stimulating protein. Plasma from septic patients induced TEC apoptosis, disruption of oxidative metabolism, alteration of cell polarity and albumin uptake, down-regulation of the tight junction protein ZO-1 and the endocytic receptor megalin on the TEC surface. These detrimental effects were significantly reduced by PFCs. Moreover, PFCs induced CD133+ renal progenitor cell proliferation and differentiation towards an epithelial/tubular-like phenotype., Conclusions: PFCs improved the viability and metabolic function of TECs seeded within a polysulphone hollow fibre and subjected to plasma from septic AKI patients. Additionally, PFCs promoted differentiation towards a tubular/epithelial phenotype of CD133+ renal progenitor cells.

Published
2018
Full Text
View/download PDF

50. Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease.

Author

Luchetti MM, Ciccia F, Avellini C, Benfaremo D, Guggino G, Farinelli A, Ciferri M, Rossini M, Svegliati S, Spadoni T, Bolognini L, Fava G, Mosca P, Gesuita R, Skrami E, Triolo G, and Gabrielli A

Subjects
Adaptor Proteins, Signal Transducing, Adult, Antigen-Antibody Complex blood, Biomarkers blood, Female, Humans, Inflammatory Bowel Diseases complications, Male, Middle Aged, Multivariate Analysis, Prospective Studies, ROC Curve, Regression Analysis, Spondylitis, Ankylosing complications, Statistics, Nonparametric, Antibodies blood, Bone Morphogenetic Proteins blood, Bone Morphogenetic Proteins immunology, Genetic Markers immunology, Immunoglobulin G blood, Inflammatory Bowel Diseases blood, Spondylitis, Ankylosing blood, Spondylitis, Ankylosing diagnosis
Abstract

Objective: The early diagnosis of inflammatory bowel disease (IBD)-associated spondyloarthritis (SpA/IBD) in patients affected by IBD represents a major topic in clinical practice; in particular, to date there are no available serum biomarkers revealing the presence of joint inflammation in these patients. Sclerostin (SOST), an antagonist of the Wnt/β-catenin pathway, and antisclerostin-immunoglobulin G (anti-SOST-IgG) have been recently studied in patients with ankylosing spondylitis (AS) as a putative marker of disease activity., Methods: SOST and anti-SOST-IgG serum levels were assayed in 125 patients with IBD, 85 with axial or peripheral SpA, and in control groups (patients with AS and rheumatoid arthritis, and healthy individuals). The diagnostic performance in discriminating the presence of SpA/IBD was assessed for both candidate biomarkers., Results: Patients affected by SpA/IBD with axial involvement displayed significantly lower levels of SOST and higher levels of anti-SOST-IgG compared to patients with only peripheral arthritis, IBD, and controls. Moreover, SOST and anti-SOST-IgG serum levels were inversely correlated and were associated with the duration of articular symptoms. Both biomarkers showed good accuracy in predicting the presence of axial SpA in patients with IBD., Conclusion: We demonstrated that in patients with IBD, SOST and anti-SOST-IgG might represent novel biomarkers to assess the presence of axial joint involvement. Moreover, the development of anti-SOST-IgG and the subsequent decrease of SOST serum levels could play a role in the pathogenesis of SpA/IBD.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results